WO1997005866A1 - Procede et composition servant a empecher la chute des cheveux apres une chimiotherapie - Google Patents

Procede et composition servant a empecher la chute des cheveux apres une chimiotherapie Download PDF

Info

Publication number
WO1997005866A1
WO1997005866A1 PCT/CA1995/000465 CA9500465W WO9705866A1 WO 1997005866 A1 WO1997005866 A1 WO 1997005866A1 CA 9500465 W CA9500465 W CA 9500465W WO 9705866 A1 WO9705866 A1 WO 9705866A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
silica
liver oil
chemotherapy
shark liver
Prior art date
Application number
PCT/CA1995/000465
Other languages
English (en)
Inventor
Jacques Giguere
Anik Desjardins
André JETTE
Original Assignee
Jacques Giguere
Anik Desjardins
Jette Andre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacques Giguere, Anik Desjardins, Jette Andre filed Critical Jacques Giguere
Priority to AU31068/95A priority Critical patent/AU3106895A/en
Priority to PCT/CA1995/000465 priority patent/WO1997005866A1/fr
Publication of WO1997005866A1 publication Critical patent/WO1997005866A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs

Definitions

  • This invention relates to the use of medium chain g-C ⁇ triglycerides containing compositions such as shark liver oil or the like for preventing the loss of hair in a person suffering from cancer and who undergoes chemotherapy.
  • the invention also relates to a therapeutic composition containing medium chain triglycerides and particles of silica.
  • the method according to the invention broadly comprises administering to that person an effective amount of a composition containing medium chain Cg-C g triglycerides.
  • the period of treatment extends at least from the start to the end of the chemotherapy. Better results will be obtained if the treatment is initiated before the start and is allowed to continue after chemotherapy.
  • compositions containing the above triglycerides may be used according to the invention, in practice it is preferred to carry out the treatment with shark liver oil which is readily available, for example under the trade-mark ECOMER, preferably in the form of doses containing shark liver oil, for example between 250 mg and 500 mg of oil per dose.
  • the preferred recommended daily dose is about nine 250 mg doses for an intake of at least up to 2500 mg/day of the composition.
  • the composition also contains silica particles, preferably in an amount such that each dose contains at least about 1 mg silica.
  • That type of silica is generally in the form of a dispersion of silicic acid anhydride, and is normally sold under the trade designation SILICEA.
  • each dose may contain about 250 to 2500 mg of shark liver oil and at least about 1 mg of silica in the form of a dispersion of silicic acid anhydride.
  • the invention is also directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a mixture of medium chain C9- C ⁇ 8 triglycerides and particles of silica, which preferably are in the form of a dispersion of silicic acid anhydride.
  • each dose may contain about 250 to 2500 mg of shark liver oil and at least about 1 mg of silica in the form of a dispersion of silicic acid anhydride.
  • the invention relates to the use of a pharmaceutical composition as defined above for preventing loss of hair in a person undergoing chemotherapy.
  • the invention relates to the use of a mixture as defined above for the preparation of a pharmaceutical composition which is useful for preventing loss of hair in a person undergoing chemotherapy.
  • patient A All during this treatment which lasted 6 months, patient A was administered daily, the equivalent of 2250 mg of shark liver oil and about 16 mg of silica as a dispersions of silicic acid anhydride. When chemotherapy was terminated patient A continued to take this preparation. There was and there is still no apparent loss of any hair.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composition contenant des triglycérides C9-C18 de chaîne moyenne, tels que de l'huile de foie de requin, seule ou combinée à des particules de silice, sous la forme, par exemple, d'une dispersion d'anhydride d'acide silicique, utile pour empêcher la chute des cheveux après une chimiothérapie.
PCT/CA1995/000465 1995-08-03 1995-08-03 Procede et composition servant a empecher la chute des cheveux apres une chimiotherapie WO1997005866A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU31068/95A AU3106895A (en) 1995-08-03 1995-08-03 Method and composition for preventing hair loss following chemotherapy
PCT/CA1995/000465 WO1997005866A1 (fr) 1995-08-03 1995-08-03 Procede et composition servant a empecher la chute des cheveux apres une chimiotherapie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA1995/000465 WO1997005866A1 (fr) 1995-08-03 1995-08-03 Procede et composition servant a empecher la chute des cheveux apres une chimiotherapie

Publications (1)

Publication Number Publication Date
WO1997005866A1 true WO1997005866A1 (fr) 1997-02-20

Family

ID=4173102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1995/000465 WO1997005866A1 (fr) 1995-08-03 1995-08-03 Procede et composition servant a empecher la chute des cheveux apres une chimiotherapie

Country Status (2)

Country Link
AU (1) AU3106895A (fr)
WO (1) WO1997005866A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1278902A (en) * 1969-02-08 1972-06-21 Sankyo Co Ointment base
EP0102534A2 (fr) * 1982-08-10 1984-03-14 Lion Corporation Agent pour la repousse des cheveux
EP0164716A2 (fr) * 1984-06-11 1985-12-18 Richardson-Vicks, Inc. Compositions limpides et stables de peroxyde de benzoyle
EP0333678A2 (fr) * 1988-01-21 1989-09-20 Hälsoprodukter Lars Kärnerud Ab Utilisation des éthers du glycérol pour le traitement des maladies allergiques
EP0461290A1 (fr) * 1990-06-14 1991-12-18 HENNING BERLIN GmbH CHEMIE- UND PHARMAWERK Capsules à couleur liquide

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1278902A (en) * 1969-02-08 1972-06-21 Sankyo Co Ointment base
EP0102534A2 (fr) * 1982-08-10 1984-03-14 Lion Corporation Agent pour la repousse des cheveux
EP0285706A1 (fr) * 1982-08-10 1988-10-12 Lion Corporation Médicament pour le traitement thérapeutique de l'alopécie
EP0164716A2 (fr) * 1984-06-11 1985-12-18 Richardson-Vicks, Inc. Compositions limpides et stables de peroxyde de benzoyle
EP0333678A2 (fr) * 1988-01-21 1989-09-20 Hälsoprodukter Lars Kärnerud Ab Utilisation des éthers du glycérol pour le traitement des maladies allergiques
EP0461290A1 (fr) * 1990-06-14 1991-12-18 HENNING BERLIN GmbH CHEMIE- UND PHARMAWERK Capsules à couleur liquide

Also Published As

Publication number Publication date
AU3106895A (en) 1997-03-05

Similar Documents

Publication Publication Date Title
JPH03501605A (ja) 痔疾並びにその他の治療用組成物
CA2186673A1 (fr) Utilisation d'acides gras dans le traitement de la choree de huntington
CA2169635A1 (fr) Methode, compositions et dispositifs pour administrer des polynucleotides nus codant des peptides biologiquement actifs
GR3033325T3 (en) Controlled release preparation containing a salt of morphine.
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
CA2070685C (fr) Methode de traitement des affections douloureuses, inflammatoires ou allergiques
US5948414A (en) Herbal based nasal spray
GB2264867A (en) Topical compositions for relief of aches and pains
CA2150185A1 (fr) Traitement des affections inflammatoires stoma-peripheriques
WO2001030802A3 (fr) Traitements therapeutiques pour des deficiences en cellules sanguines
AU3601897A (en) Novel formulations for the administration of fluoxetine
CA2274510A1 (fr) Traitement de l'arthrose par administration de poly-n-acetyl-d-glucosamine
JPS6047246B2 (ja) うつ病治療薬
US20060251731A1 (en) Therapeutic herbal lozenge composition
JP2003514025A5 (fr)
Engelsman et al. Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an EORTC study.
US5886047A (en) Topical pharmaceutical preparation for fever blisters and other viral infections and method of use
Bardsley et al. Two years treatment with almitrine bismesylate in patients with hypoxic chronic obstructive airways disease
WO1997005866A1 (fr) Procede et composition servant a empecher la chute des cheveux apres une chimiotherapie
WO2001068076A8 (fr) Enantiomere en d de la dfmo et ses procedes d'utilisation
Biermann et al. Comparison of spiramycin and doxycycline in the treatment of lower respiratory infections in general practice
US5968518A (en) Composition and method for treating premenstrual syndrome
CA2403674A1 (fr) Utilisation de triiodothyronine pour le traitement de l'insuffisance cardiaque congestive
Johnston et al. Inhibition of adrenal steroidogenesis by glutethimide
Janicak et al. Verapamil for acute mania: preliminary results from a double-blind, placebo-controlled study

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA